How do the 182,584-share ISCO options granted to Paul V. Maier vest?

The 182,584-share option vests on the earlier of June 11, 2027 or the date of the next annual meeting of International Stem Cell Corp stockholders after the grant date, creating a single vesting event tied to time or corporate governance timing.

What is the vesting schedule for the 30,000-share ISCO option grant to Paul V. Maier?

The 30,000-share stock option grant vests in equal quarterly increments through June 11, 2027. The first quarterly vesting increment occurs on September 11, 2026, spreading the award’s vesting over several dates instead of one cliff.

International Stem Cell (ISCO) director receives long-dated stock option grants

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

International Stem Cell Corp director Paul V. Maier received new stock option awards as compensation. On June 11, 2026 he was granted options to buy 182,584 shares of common stock at an exercise price of $0.178 per share and a separate grant for 30,000 shares at $0.17 per share, all expiring on June 11, 2036. One grant vests in full on the earlier of June 11, 2027 or the next annual stockholder meeting after the grant date, while the other vests in equal quarterly increments through June 11, 2027, starting September 11, 2026. These are awards, not open‑market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider MAIER PAUL V

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	182,584	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 shares (Direct, null)

Footnotes (1)

The shares underlying such option shall vest on the earlier of (a) June 11, 2027, or (b) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. The shares underlying such option shall vest in equal quarterly increments through June 11, 2027, with the first increment vesting on September 11, 2026.

Key Figures

Option grant size: 182,584 options Exercise price: $0.178 per share Second option grant size: 30,000 options +3 more

6 metrics

Option grant size 182,584 options Stock Option (Right to Buy) grant on June 11, 2026

Exercise price $0.178 per share Conversion/exercise price for 182,584-share option grant

Second option grant size 30,000 options Additional Stock Option (Right to Buy) grant on June 11, 2026

Second exercise price $0.17 per share Conversion/exercise price for 30,000-share option grant

Option expiration June 11, 2036 Expiration date for both reported option grants

Vesting start date September 11, 2026 First quarterly vesting date for 30,000-share option grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, vest in equal quarterly increments, underlying security

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest in equal quarterly increments financial

"The shares underlying such option shall vest in equal quarterly increments through June 11, 2027"

underlying security financial

"underlying_security_title: Common Stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 08:31 PM Accepted by SEC EDGAR 06/23/2026 - 08:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAIER PAUL V

(Last)

(First)

(Middle)

C/O INTERNATIONAL STEM CELL CORP.

9745 BUSINESSPARK AVENUE

(Street)

SAN DIEGO

CALIFORNIA

92131

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
International Stem Cell CORP [ ISCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.17	06/11/2026		A		30,000		⁽¹⁾	06/11/2036	Common Stock	30,000	$0.00	30,000	D
Stock Option (Right to Buy)	$0.178	06/11/2026		A		182,584		⁽²⁾	06/11/2036	Common Stock	182,584	$0.00	182,584	D

Explanation of Responses:

1. The shares underlying such option shall vest on the earlier of (a) June 11, 2027, or (b) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.

2. The shares underlying such option shall vest in equal quarterly increments through June 11, 2027, with the first increment vesting on September 11, 2026.

	/s/ Russell Kern, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ISCO director Paul V. Maier report on this Form 4?

Paul V. Maier reported receiving two stock option grants. One covers 182,584 shares and the other 30,000 shares of International Stem Cell Corp common stock, both granted on June 11, 2026 as awards rather than open-market trades.

What are the exercise prices of the new ISCO stock options granted to Paul V. Maier?

The reported options have exercise prices of $0.178 and $0.17 per share. Each grant covers a separate block of shares and gives Maier the right to buy common stock at those fixed prices until expiration.

When do Paul V. Maier’s new ISCO stock options expire?

Both reported option grants expire on June 11, 2036. This long-dated expiration provides a multi-year window in which Maier can choose to exercise his rights to buy International Stem Cell Corp common stock at the specified prices.

Does this ISCO Form 4 show Paul V. Maier buying or selling shares on the market?

No, the Form 4 shows grant or award acquisitions of stock options, not open-market buying or selling. The transactions are coded as awards (code A), reflecting compensation rather than trading in International Stem Cell Corp shares.